赛隆药业(002898) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥62,208,999.46, a decrease of 8.91% compared to ¥68,294,367.60 in the same period last year[3]. - Net profit attributable to shareholders was ¥1,280,860.47, down 37.93% from ¥2,063,525.67 year-on-year[3]. - Basic and diluted earnings per share were both ¥0.0073, representing a decrease of 37.61% from ¥0.0117[3]. - The company reported a net profit of CNY 1,949,800.33 for Q1 2022, down from CNY 3,720,160.91 in Q1 2021, a decrease of 47.6%[17]. - The total profit for Q1 2022 was CNY 1,950,178.07, a decrease from CNY 3,589,229.45 in Q1 2021, representing a decline of approximately 45.4%[18]. - The net profit for Q1 2022 was CNY 1,280,860.47, down from CNY 2,063,525.67 in Q1 2021, indicating a decrease of about 37.8%[18]. - Basic and diluted earnings per share for Q1 2022 were both CNY 0.0073, compared to CNY 0.0117 in Q1 2021, reflecting a decline of approximately 37.5%[19]. Cash Flow - The net cash flow from operating activities was -¥19,037,470.33, a decline of 255.27% compared to ¥12,261,248.72 in the previous year[3]. - The company’s cash flow from operating activities showed a significant decline, impacting liquidity and future investment capabilities[17]. - The net cash flow from operating activities for Q1 2022 was negative CNY 19,037,470.33, compared to a positive CNY 12,261,248.72 in Q1 2021[22]. - Total cash outflow from operating activities in Q1 2022 was CNY 62,979,372.33, an increase from CNY 44,568,886.91 in Q1 2021[22]. - Cash inflow from investment activities in Q1 2022 was CNY 3,589,436.43, up from CNY 693,338.80 in Q1 2021[22]. - The net cash flow from investment activities for Q1 2022 was negative CNY 2,231,243.99, compared to negative CNY 9,993,966.85 in Q1 2021, showing an improvement[22]. - Cash inflow from financing activities in Q1 2022 was CNY 49,993,513.00, down from CNY 83,400,000.00 in Q1 2021[22]. - The net cash flow from financing activities for Q1 2022 was negative CNY 2,736,297.99, a significant decrease from positive CNY 42,032,057.55 in Q1 2021[22]. - The ending cash and cash equivalents balance for Q1 2022 was CNY 89,272,183.43, down from CNY 102,096,944.27 in Q1 2021[22]. Assets and Liabilities - Total assets at the end of the reporting period were ¥871,767,667.14, down 1.25% from ¥882,784,590.43 at the end of the previous year[3]. - The total assets of the company decreased to CNY 871,767,667.14 from CNY 882,784,590.43, a reduction of 1.3%[14]. - Total liabilities decreased to CNY 306,825,766.11 from CNY 319,123,549.87, a decline of 3.8%[15]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 25,049[10]. - The largest shareholder, Cai Nangu, holds 51.15% of the shares, amounting to 90,016,937 shares[10]. Operating Costs and Expenses - Total operating costs for Q1 2022 were CNY 62,774,886.07, down from CNY 65,100,993.58 in the previous year, reflecting a reduction of 3.9%[17]. - The company's gross profit margin decreased, with gross profit for Q1 2022 at CNY -565,886.61 compared to CNY 1,193,374.02 in Q1 2021[17]. - Research and development expenses for Q1 2022 were CNY 4,142,780.79, down from CNY 5,030,369.69, a decrease of 17.7%[17]. - The company reported a significant increase in financial expenses, which rose by 165.76% to ¥1,960,562.84 due to increased bank loan interest[8]. Fair Value Changes - The fair value change income was ¥4,020,856.24, an increase of 288.61% compared to ¥1,034,666.62 in the previous year[8]. Return on Equity - The weighted average return on equity was 0.23%, a decrease of 0.12% from 0.35%[3].